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Abstract 1 
Physiotherapy remains the cornerstone of cystic fibrosis (CF) management alongside medical 2 
treatment. Traditionally, physiotherapy intervention focussed on airway clearance during the 3 
clinically stable stage and chest infections. Research evidence consistently supports greater mucus 4 
clearance with chest physiotherapy compared to cough alone or no treatment. Various methods and 5 
techniques of airway clearance have been developed and investigated, and data suggest that most of 6 
them are of similar effectiveness. Nowadays physiotherapy management also extends to other areas, 7 
supported by studies and clinical practice. The physiotherapists plan, supervise and follow-up 8 
systematic exercise or personalised rehabilitation programs, which, similarly to airway clearance, 9 
are recommended in all patients with CF. Furthermore, based on a comprehensive assessment, 10 
physiotherapists incorporate the management of accompanying musculoskeletal problems such as 11 
back pain and postural disorders, as well as urine incontinence issues. In the era that aims to improve 12 
quality of life, it is essential that physiotherapists are aware of specific conditions that might affect 13 
the management of CF. Their role is to work alongside and within the CF multi-disciplinary team 14 
throughout patient’s treatment and consistently support the patient and carers, in particular whilst 15 
on clinical pathways of the lung transplantation and palliative care. 16 
 17 
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3 
INTRODUCTION 19 
Cystic fibrosis (CF) is a recessive genetic disease that affects the patient on multiple systems, with 20 
profound manifestations in the respiratory and digestive systems [1]. It is characterised by the 21 
mutation and therefore dysfunction of the gene for the cystic fibrosis transmembrane conductance 22 
regulator (CFTR). This protein mainly functions as an ion channel, regulating fluid volume on 23 
epithelial surfaces via chlorine secretion and inhibition of sodium resorption. In the airways of the 24 
patients with CF, dysfunction of the CFTR results in periciliary liquid layer depletion [2]. Clinically, 25 
patients with CF present abnormal consistency and high volumes of sputum, cough, dyspnoea, 26 
bronchiectasis and weight loss. As the survival of these patients is increasing, it is crucial that health 27 
care professionals address symptoms and support individuals in evolving issues developed 28 
throughout their life span. 29 
 30 
Physiotherapy is an integral part of the therapeutic management of CF patients, both at the clinically 31 
stable stage of the disease and during respiratory infections. In the past, physiotherapy was focused 32 
on airway clearance, also known as chest physiotherapy, by teaching or applying methods such as 33 
the postural drainage with or without the additional application of manual techniques [3]. Postural 34 
drainage of the tracheobronchial tree uses specific gravitational positions to assist mucus 35 
mobilisation downwards (towards the mouth) within the airways. Manual techniques (percussions, 36 
vibrations and/or shakes) use mechanical forces to assist the detachment of mucus from the airway 37 
epithelium and its mobilisation. Nowadays, the choice of airway clearance techniques has been 38 
expanded to methods such as the autogenic drainage, the active cycle of breathing techniques 39 
(ACBT), the use of positive expiratory pressure (PEP) devices with or without oscillation, and 40 
others. Still, modern physiotherapy in CF also includes the assessment of the cardiovascular system 41 
and improvement of the patient’s fitness level, muscle strength and endurance through exercise, as 42 
well as specialised interventions to improve musculoskeletal symptoms of pain, posture and 43 
incontinence [4]. 44 
4 
 45 
PHYSIOTHERAPY 46 
Airway clearance 47 
Patient education, application and monitoring of the airway clearance techniques remain the main 48 
physiotherapy treatment for patients with CF [4]. Physiotherapists facilitate the establishment of an 49 
individualised airway clearance routine by supporting patients and their families to establish regular 50 
regimes during a clinically stable stage and have an escalation plan for disease exacerbations [5]. 51 
Airway clearance is usually performed on a daily basis and as required. The selected method applied, 52 
duration and frequency of each session are tailored to the patient, their general health condition 53 
and the severity of the disease. For instance, airway clearance becomes more regular during 54 
exacerbations or hospitalisations [6]. Hospitalisations also provide an opportunity for 55 
physiotherapists to re-assess the effectiveness of daily airway clearance and provide appropriate 56 
feedback and guidance for improving the patient’s usual technique prior to discharge.  57 
 58 
Table 1 presents the main categories of airway clearance techniques and methods in CF. These can 59 
be used in isolation or in combination regimes. Assessment of effectiveness is based on measuring 60 
sputum volume or weight, lung function by spirometry, frequency of hospitalisations and quality of 61 
life. Airway clearance is extensively supported in the literature when compared to no airway 62 
clearance or cough alone [4, 7-9]. A recent systematic review supported a significant increase in the 63 
amount of sputum (wet or dry) in the patient groups that applied airway clearance using postural 64 
drainage with or without the addition of manual techniques or using PEP, compared to spontaneous 65 
cough or not using any technique [7]. The weight of the sputum was higher after the application of 66 
the active cycle of breathing techniques compared to the use of the flutter (an oscillating PEP device) 67 
or high frequency chest wall oscillation (vest) [10]. The weight of the sputum expectorated was 68 
greater after using the PEP mask compared to autogenic drainage, postural drainage positions and 69 
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their combination, although this difference was short-term (up to one week) [11]. On the other hand, 70 
there was no difference in the amount of the expectorated mucus after autogenic drainage compared 71 
to the flutter, or between the high frequency chest wall oscillation compared to the autogenic 72 
drainage or the PEP mask for longer time-intervals [10, 12].  73 
 74 
Systematic reviews did not show significant differences in the lung function (FEV1) of adult patients 75 
following the use of PEP, when assessed patients prior and immediately after a physiotherapy 76 
session or up to 3 months later [7, 10, 11, 13]. Additionally, the lung function did not change after 77 
applying the active cycle of breathing techniques in combination with the PEP mask, postural 78 
drainage with or without manual techniques, or the high frequency chest wall oscillation [12]. 79 
However, treatment in children and adolescents that was applied up to one year showed 6% increase 80 
in FEV1 with the use of PEP [13].  81 
 82 
Regarding the hospitalisation frequency, no differences were found for those who practiced the 83 
active cycle of breathing techniques compared to the postural drainage with or without manual 84 
techniques [12]. The number of hospitalisations, however, was lower for those who used PEP than 85 
the patients who used the flutter (5 vs 18 hospitalisations, respectively) [10]. Similarly, fewer 86 
patients used intravenous antibiotics from the group that used PEP devices, compared to the group 87 
of the high frequency chest wall oscillation [13]. 88 
 89 
For the quality of life, there is no difference amongst techniques and devices, such as the postural 90 
drainage with or without manual techniques, active cycle of breathing techniques, autogenic 91 
drainage, PEP mask, flutter, and cornet [10, 12, 13]. However, patients preferred the PEP mask for 92 
long-term use (>1 month), and also preferred seating instead of using postural drainage positions 93 
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[10, 11, 13]. Autogenic drainage was preferred among children between 12-18 years old, compared 94 
to postural drainage in combination with manual techniques [14].  95 
 96 
Important factors for the success of the selected airway clearance plan are the compliance to 97 
treatment and patient satisfaction. Factors that increase the rate of compliance are good patient 98 
knowledge of the technique and confidence in its application, independence and preference [15, 16]. 99 
Evidence indicate that patients who receive help, those who produce more sputum, and children 100 
with CF whose parents believe in the necessity of treatment are those with higher compliance in 101 
airway clearance [17, 18].  102 
 103 
Airway clearance adaptations 104 
Mucolitics and other agents 105 
Patients with CF often receive medications that aim to increase the effectiveness of airway 106 
clearance, such as nebulised hypertonic saline (3% to 7% NaCl), dornase alpha (DNase), and 107 
mannitol. The use of inhaled hypertonic saline (osmotic pressure > 0.9% NaCl) in patients with CF 108 
is considered to improve the rheological characteristics of sputum and increase the hydration of the 109 
airway epithelium; thus, increase the sputum motility and facilitate the mucus clearance [19]. There 110 
is good evidence that the use of hypertonic saline reduces the incidence of respiratory infections, 111 
increases FEV1, and improves the quality of life, although the changes are not maintained in the 112 
long term (48 weeks) [20, 21]. During the hospitalisation of patients with CF, hypertonic saline 113 
improves the chances of quick return of the lung function (FEV1) to pre-infectious levels [22]. With 114 
regards to timing the hypertonic saline administration, a recent systematic review supports its use 115 
before or during the performance of airway clearance, rather than its administration afterwards [23]. 116 
If the prescribed doses are two, it is recommended to administer one in the morning and one in the 117 
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evening, and if the patient receives a single dose this is given at a convenient time chosen by the 118 
patient [23]. 119 
 120 
Dornase alpha (DNase) is a recombinant human deoxyribonuclease that reduces sputum viscosity 121 
by selectively hydrolysing the large extracellular DNA molecules contained in the mucus into 122 
smaller structures, thereby increasing the potential for its elimination [24]. This drug is administered 123 
via a jet-nebuliser device and has been shown to reduce the incidence of respiratory infections, 124 
increase respiratory function, and improve quality of life [24]. With regards to timing its 125 
administration, it appears that using DNase before or after airway clearance does not have any 126 
difference in improving lung function (FEV1 and FVC) or patient's quality of life [25, 26]. In clinical 127 
practice, physiotherapy often follows the proposed guidelines of the pharmaceutical company to 128 
perform airway clearance 30 minutes after the DNase administration [27]. 129 
 130 
Inhaled mannitol is a naturally occurring sugar alcohol which enhances osmosis, causing mucus 131 
hydration [28]. Inhaled mannitol is administered as dry powder (capsules) using an inhaler. As 132 
demonstrated by two 26-week multi-centre studies with a total number of 600 participants with CF, 133 
inhaled mannitol improves the respiratory function of patients but does not improve their quality of 134 
life [29, 30]. Although its use usually precedes airway clearance in clinical practice, there is no 135 
research data to compare different timings of administration. 136 
 137 
Haemoptysis 138 
Haemoptysis is a major change in the patient's clinical presentation and may be life-threatening. The 139 
physiotherapy assessment should include questions about sputum description and reference to 140 
current or past haemoptysis episodes. Active frank haemoptysis (>100-1000 ml haemoptysis in 24 141 
hours or 48 hours) is treated exclusively medically, e.g. with bronchial embolisation of the arteries 142 
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or thoracic surgery, while the airway clearance treatment is temporarily discontinued [31, 32]. In 143 
moderate or low haemoptysis, physiotherapists, in collaboration with the medical team, decide 144 
whether or not it is appropriate to continue airway clearance using clinically reasoning. If the 145 
treatment is appropriate and safe to continue, then the active cycle of breathing techniques or 146 
autogenic drainage is often selected over other techniques. 147 
 148 
Pneumothorax 149 
Spontaneous pneumothorax is a common complication in patients with CF. It is associated with a 150 
reduction in pulmonary function and 50-90% chance of recurrence [32, 33]. If the pneumothorax 151 
occurs for the first time and it is small, then it can be treated conservatively with oxygen supply 152 
[34]. In patients continuing airway clearance, it is suggested to liaise with the medical team for 153 
adding humidification to the oxygen supply and ensuring adequate analgesia for the duration of the 154 
treatment sessions [35]. In the case of large pneumothorax (>2 cm between parietal pleura and 155 
visceral pleura) or recurrent pneumothorax, chest drainage is performed using thoracic catheters, 156 
while patients might get pleurodesis in resistant cases [34]. Positive pressure devices such as PEP, 157 
flutter and acapella are contraindicated in the presence of pneumothorax [34]. Regarding physical 158 
activity, patients need to be engaged with moderate activities but should avoid bearing weights over 159 
2 kg or strenuous aerobic exercise for a period of two to six weeks after the complete drainage of 160 
the pneumothorax [34]. 161 
 162 
Exercise 163 
Exercise is an integral part of the comprehensive physiotherapy intervention for patients with CF 164 
[36].  American College of Sports Medicine guidelines advocate 3-5 sessions of moderate exercise 165 
per week, with the aim to adopt exercise as a way of living [37]. Benefits of specific exercise 166 
modalities in cystic fibrosis are yet to be identified in methodologically strong studies [38]. Despite 167 
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research interest, evidence has not established the effectiveness of inspiratory muscle training on 168 
this group of patients, therefore this is currently not routinely incorporated in the CF treatment. In 169 
the clinical setting, the assessment of patients with CF uses simple and cost-effective exercise field 170 
tests, such as the 6-minute walk test (6MWT) and the incremental shuttle walk test (ISWT), whilst 171 
the level of dyspnoea is assessed using the Borg dyspnoea scale [39].  172 
 173 
Exercise can theoretically assist airway clearance through the kinetic forces and vibrations generated 174 
within the airways, but it cannot substitute for the formal airway clearance [40]. When compared to 175 
airway clearance techniques, moderate aerobic exercise leads to less mucus expectoration [41]. 176 
Also, exercise as a single agent does not increase cough immediately after its completion, although 177 
it improves the subjective ease of sputum clearance [42]. Clinically, exercise is mainly used 178 
additionally to airway clearance, as a means to improve the exercise capacity of the patient and is 179 
usually performed before the implementation of airway clearance. 180 
 181 
Exercise considerations 182 
Musculoskeletal and postural issues 183 
Back and thoracic pain are frequently reported in patients with CF, although they do not have an 184 
effect on lung function [43, 44]. Higher thoracic kyphosis is associated with lower lung function, 185 
but nowadays it is more uncommon compared to a few years ago [45]. Low bone density and 186 
osteopenia is also a common issue in patients with CF [46, 47]. Counselling and appropriate exercise 187 
programs from physiotherapists can potentially address and improve these postural and structural 188 
issues [36].  189 
 190 
Urinary incontinence 191 
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Surveys show that urinary incontinence in patients with CF is reported in 30% to 68% of women or 192 
girls and 5% to 16% of men or boys [48-51]. The dynamic pressure created during coughing is 193 
potentially a key mechanism of CF urinary incontinence, although it may not be the only one [52]. 194 
Coughing, sneezing, laughing and spirometry are among the activities that trigger urinary 195 
incontinence incidents [53]. Incontinence worsens during respiratory infections and has been 196 
associated with poorer quality of life and higher anxiety and depression scores [51, 54, 55]. 197 
Assessing incontinence using screening tools and clarifying questions should be an integral part of 198 
the CF physiotherapy assessment, regardless of gender [56]. Physiotherapy treatment of urinary 199 
incontinence includes counselling and specialised training involving pelvic floor exercises, such as 200 
Kegel exercises [55, 57, 58]. 201 
 202 
Diabetes mellitus 203 
Diabetes mellitus is associated with CF and is the most common comorbidity of the disease, 204 
occurring in up to 20-50% of adult patients [59-61]. This comorbidity requires the co-operation of 205 
the physiotherapists with the endocrine team, especially for the patients who require insulin therapy 206 
[62]. Additionally, the presence of diabetes mellitus needs to be considered in the physiotherapy 207 
plan, mainly in the exercise prescription and performance. In this case, the proper scheduling of the 208 
meal times or insulin intake is essential. 209 
 210 
Quality of life 211 
Over time and as the CF severity and symptoms progress, the quality of life of patients is 212 
deteriorating. Females with CF often report poorer quality of life compared to their male age-213 
matched peers [63]. Although the correlation between lung function and quality of life is weak to 214 
moderate, patients with better lung function report higher quality of life [54]. Also, the presence of 215 
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Pseudomonas aeruginosa and frequent respiratory infections appear to have a negative impact on 216 
the quality of life of patients [54].  217 
 218 
Researchers and clinicians can use a number of validated questionnaires for the assessment of 219 
quality of life in people with CF. Those include: generic questionnaires or questionnaires for a 220 
specific disease symptom, such as the Short Form-36 (SF-36) and the Leicester Cough 221 
Questionnaire, respectively [64, 65]; disease-specific questionnaires, such as the Manchester 222 
Questionnaire, the Cystic Fibrosis Questionnaire-Revised and the Cystic Fibrosis-Quality of Life 223 
[64, 66-69]; and questionnaires for babies and children of young age, such as the Modified Parent 224 
Cystic Fibrosis Questionnaire-Revised [70].  225 
 226 
Special considerations  227 
Long term oxygen therapy and non-invasive ventilation 228 
A recent systematic review in patient with CF did not show long-term benefits from the long-term 229 
oxygen therapy, in survival, respiratory function or cardiovascular health, although it showed 230 
improved school or work attendance rates [71]. When oxygen is administered during exercise only, 231 
it helps to improve oxygenation, reduces the feeling of dyspnoea and increases the duration of the 232 
exercise [71, 72]. However, supplemental oxygen during exercise in patients with initially low 233 
arterial oxygen values  appears to cause hypercapnia in the short term (PCO2 up to 16 mmHg) [71]. 234 
Also, oxygen therapy during sleep improves oxygenation, but is accompanied by small hypercapnia 235 
[71]. The use of supplemental oxygen should follow the established clinical guidelines that are based 236 
on hypoxia (PaO2 ≤55 mmHg or 60 mmHg) and the presence of clinical symptoms [73].  237 
 238 
Non-invasive ventilation (NIV) is used in patients with CF on respiratory failure, hypoventilation 239 
during sleep, as well as a bridge to lung transplantation [3]. For patients with severe clinical 240 
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presentation where airway clearance causes fatigue and high levels of dyspnoea, NIV can be used 241 
to assist airway clearance [74]. The use of NIV during the physiotherapy session facilitates mucus 242 
expectoration and reduces the sensation of dyspnoea during the treatment compared to other 243 
techniques particularly for patients with low lung function [75]. However, the long-term effects of 244 
NIV on airway clearance need further investigation [76]. 245 
 246 
Paediatric population 247 
Choosing a treatment plan for children with CF is based on age, clinical presentation and certain 248 
social criteria [77]. There is no agreement on the most appropriate starting age for airway clearance. 249 
A proposal for early disease management (pre-symptomatic) is to carefully monitor the clinical 250 
presentation of children and adopt an active treatment plan following the onset of symptoms [78]. 251 
At young ages, where the child can not follow instructions and cooperate, assisted autogenic 252 
drainage or PEP devices with a child mask can be used. Physiotherapists are also responsible for 253 
educating the child's parents or carers for appropriate evaluation of the child’s symptoms and 254 
treatment implementation as required [79]. Postural drainage with tilt (head-down positions) is no 255 
longer advised for babies, as it has been shown to increase the gastroesophageal reflux [80]. 256 
 257 
As children grow older, they can more actively participate in their treatment. Children over 3 years 258 
old can also use an airway clearance game, the bubble PEP. This is a positive-pressure breathing 259 
home-made device, where children are encouraged to generate soap bubbles by breathing out 260 
through a small plastic tube and into a bottle of soapy water [81]. According to the UK Cystic 261 
Fibrosis Foundation, at the age of 6 years or more, the use of nebulised hypertonic saline can be 262 
initiated in combination with airway clearance [82]. Also, at all ages, activity games and 263 
engagement with exercise are encouraged and used, for instance racing, trampolines and exercises 264 
using a gym ball [83]. 265 
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 266 
Palliative care 267 
CF is a disease that limits life expectancy and requires discipline and consistency to many hours of 268 
daily treatment. As a result, its psychological impact should not be ignored [84]. If patients are in 269 
respiratory failure and in lung transplantation list, pulmonary rehabilitation is the treatment priority, 270 
alongside the aim to relieve symptoms. Working in line with the patient’s wishes is very important, 271 
particularly during the palliative care stage. Airway clearance of less active patient participation (eg. 272 
postural drainage), massage and some dyspnoea relieving positions could be applied during this 273 
stage, if they provide comfort to the patient [85]. 274 
 275 
CONCLUSIONS 276 
CF management is highly demanding, mainly aiming to the reduction and treatment of chest 277 
infections, improvement of quality of life and increase of life expectancy. Physiotherapy is an 278 
integral part of the patient’s daily treatment routine, and additionally to airway clearance other 279 
important issues should be addressed. International clinical guidelines suggest access to specialised 280 
physiotherapy care both during a clinically stable stage of the disease and during respiratory 281 
infections. At the clinically stable stage, patients should be evaluated by physiotherapists every 3-6 282 
months to re-evaluate and optimize their treatment plan. During respiratory infections, 283 
physiotherapy interventions are intensified according to the clinical presentation. Although in CF 284 
airway clearance is the cornerstone of physiotherapy treatment, physiotherapists work beyond the 285 
respiratory system and play an important role in the management of other issues, mainly using 286 
individualised exercise programmes. The exercise programmes need to be tailored to patient-related 287 
needs and issues, such as pain, diabetes and incontinence. This way, the patient-centred and 288 
individualised treatment follows the international standards and clinical guidelines. 289 
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Table 1. Common airway clearance techniques and methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Airway clearance techniques 
Postural drainage 
Manual techniques 
Active circle of breathing techniques (ACBT) 
Autogenous drainage (AD) 
Positive expiratory pressure (PEP) devices (PEP mask, Pari-PEP, etc) 
Positive expiratory pressure (PEP) devices with oscillation (flutter, acapella, cornet, etc.) 
Intermittent Positive Pressure Breathing (IPPB) 
High frequency chest wall oscillation (HFCWO) or vest 
Non-invasive mechanical ventilation (NIV) 
Aerobic exercise 
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